Compliance of Patients With Essential Hypertension Treated With Candesartan or Candesartan/Hydrochlorothiazide

Condition(s) targeted: Essential Hypertension

Phase: N/A

Status: Completed

Sponsored by: AstraZeneca

Official(s) and/or principal investigator(s):
R. E. Schmieder, MD, Principal Investigator, Affiliation: University hospital Erlangen-Nurnberg
Andrea Pahor, MD, Study Chair, Affiliation: MED Dep., AstraZeneca Germany

The CoCa study with at maximum daily dose of 32 mg candesartan or 16/12. 5 mg candesartan/hydrochlorothiazide has the objective to evaluate under naturalistic conditions, i. e. under routine medical care conditions, the subject compliance as well as the efficacy and tolerability of candesartan or candesartan/HCT in subjects suffering from essential hypertension.

Official title: Compliance of Patients With Essential Hypertension Treated With Candesartan or Candesartan/Hydrochlorothiazide

Study design: Cohort, Prospective

Primary outcome: To estimate under naturalistic conditions the compliance rate, defined as the number of subjects with regular intake of the prescribed dose of candesartan or candesartan/HCT as judged by the physician at the end of the observational period.

Secondary outcome:

To assess under naturalistic conditions the subject's reason(s) for being compliant or non-compliant with the intake of the pre-scribed dose of candesartan or candesartan/HCT

To assess under naturalistic conditions the subject's reason(s) for withdrawal of the pre-scribed dose of candesartan or candesartan/HCT

To assess under naturalistic conditions whether physicians are using procedures to improve the subject's compliance regarding the intake of candesartan or candesartan/HCT and to get insight in the type and effects of these procedures

Minimum age: N/A. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- essential hypertension

- under candesartan treatment

Exclusion Criteria:

-

Starting date: January 2007
Ending date: September 2007
Last updated: February 5, 2008